Abzena, an end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has appointed Moncef Slaoui, PhD, to its ...

Agreement grants Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet ...

Enhancing its peptide synthesis capabilities to meet increasing demand from its global partners for efficient and scalable ...

Esphera SynBio, a pre-clinical stage synthetic biology company, has launched a new project aimed at enhancing the efficacy of ...

Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its ...

Harbour BioMed, a global biopharmaceutical company, and Sichuan Kelun Biotech BioPharmaceutical have entered into a license ...

Excipient GMP certification validates the company's quality systems and process controls to support the cell and gene therapy ...

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.